Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for CA 125 tumor antigen testing by immunoassay, effective May 15, 2026. Here's what billing teams need to know before that date.
CA 125 is one of the most billed tumor markers in oncology and gynecologic practices. CMS CA 125 coverage policy changes affect how you document medical necessity, which diagnoses support a covered claim, and whether your current billing guidelines hold up under review. The policy does not list specific CPT or HCPCS codes in the available data — we'll address that directly in the codes section. What matters right now is that this change is live in May 2026, and your billing team needs to act before the effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Tumor Antigen by Immunoassay — CA 125 |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Gynecologic oncology, medical oncology, obstetrics & gynecology, internal medicine, laboratory billing |
| Key Action | Review CA 125 billing guidelines and documentation standards before May 15, 2026 |
CMS CA 125 Coverage Criteria and Medical Necessity Requirements 2026
CA 125 is a glycoprotein antigen used primarily to monitor ovarian cancer. CMS covers it — but not broadly. The Centers for Medicare & Medicaid Services ties CA 125 reimbursement tightly to documented medical necessity. That means the diagnosis on the claim has to do real work.
CMS CA 125 coverage policy is built around specific clinical scenarios. Monitoring response to treatment in a patient with a confirmed ovarian cancer diagnosis is the clearest covered indication. So is follow-up surveillance after first-line therapy. Those are your strongest billing positions.
Where billing teams run into claim denial is in the screening context. CMS does not cover CA 125 as a general cancer screening tool, even for high-risk patients without a prior diagnosis. If your ordering provider is using it that way, your documentation has to be airtight — and in most cases, the claim will not hold up under review.
Medical necessity documentation should reference the patient's diagnosis, their treatment history, and the clinical rationale for ordering the test at that specific point in care. Vague or templated notes don't support CA 125 billing under Medicare. A note that says "monitor tumor marker" without connecting it to an active or recently treated malignancy is a liability.
Prior authorization is not typically required for CA 125 under Medicare fee-for-service. However, Medicare Advantage plans administered through private insurers may have their own prior authorization rules. If your patients are on Medicare Advantage, verify those requirements separately — they do not follow the same CMS national coverage rules.
Local coverage determinations also play a role here. Your Medicare Administrative Contractor may have issued an LCD that adds criteria beyond what the national policy states. Check with your MAC before May 15, 2026 to confirm whether a local coverage determination applies in your region.
CMS CA 125 Exclusions and Non-Covered Indications
Not every CA 125 order qualifies for Medicare reimbursement. CMS draws a hard line on several use cases.
Screening in asymptomatic patients is not covered. This applies even when a patient has a family history of ovarian cancer or a known BRCA mutation. The absence of a confirmed diagnosis is enough to make the claim non-covered.
Diagnostic workup without a supporting diagnosis code is another common denial driver. If the ordering provider suspects ovarian cancer but no diagnosis has been confirmed, the claim needs to reflect that with the appropriate suspected or rule-out coding language. Claims submitted with a confirmed malignancy code when the diagnosis hasn't been established yet create compliance exposure.
Repeated testing outside clinical guidelines is a gray area, but CMS and its contractors watch for it. If your practice is ordering CA 125 more frequently than the patient's treatment protocol supports, expect scrutiny. Document the clinical rationale for every order.
If any of these situations describe your current ordering patterns, talk to your compliance officer before May 15, 2026. This is the kind of thing that looks fine in isolation but creates audit risk at volume.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Monitoring treatment response in confirmed ovarian cancer | Covered | See codes section | Medical necessity documentation required; active or recent treatment history must be documented |
| Post-treatment surveillance after first-line ovarian cancer therapy | Covered | See codes section | Surveillance interval must align with clinical guidelines |
| Screening in asymptomatic patients (including high-risk) | Not Covered | N/A | No coverage even with BRCA mutation or strong family history |
| Diagnostic workup — unconfirmed malignancy | Not Covered / Conditional | N/A | Correct ICD-10 coding critical; do not use confirmed malignancy codes for suspected diagnoses |
| Monitoring for non-ovarian malignancies | Conditional | See codes section | Coverage depends on MAC LCD and documented clinical rationale |
| Routine testing without documented clinical rationale | Not Covered | N/A | Frequency and clinical necessity must be documented per order |
Coverage status is based on CMS national policy and general Medicare billing guidelines. MAC-level local coverage determinations may add or restrict indications in your region.
CMS CA 125 Billing Guidelines and Action Items 2026
The modified policy is effective May 15, 2026. That gives your billing team a specific deadline to work against. Here are the steps to take now.
| # | Action Item |
|---|---|
| 1 | Audit your CA 125 claims from the last 12 months. Pull all claims where CA 125 was billed and check the diagnosis codes attached. Flag any claims where the diagnosis doesn't clearly support covered use — monitoring of a confirmed malignancy or post-treatment surveillance. If you find patterns, address them before the effective date. |
| 2 | Update your order templates and requisition forms. Make sure the ordering interface prompts providers to document the clinical indication — not just the test name. The note needs to show an active or recent cancer diagnosis and a clear reason for ordering at that point in the patient's care. |
| 3 | Review ICD-10 code usage across your CA 125 orders. Confirmed malignancy codes versus suspected or rule-out codes matter here. Using a confirmed ovarian cancer code when the diagnosis is still being established is a coding error with compliance consequences. Train your coders on the distinction before May 15, 2026. |
| 4 | Check your MAC's local coverage determination. The CMS national policy sets the floor. Your Medicare Administrative Contractor may have an LCD with additional criteria. Go to the CMS LCD database or contact your MAC directly. Do this before the effective date — not after your first denial. |
| 5 | Verify prior authorization rules for Medicare Advantage patients. CMS fee-for-service doesn't require prior authorization for CA 125 billing. Medicare Advantage plans do their own thing. Pull a list of your Medicare Advantage payers and confirm their requirements separately. This is a common source of avoidable claim denial. |
| 6 | Brief your ordering providers on the covered indications. Providers don't always know where the coverage line sits. A short internal communication — or a note in the EHR ordering workflow — that lists the covered versus non-covered indications keeps everyone aligned and reduces the documentation gaps your billing team has to clean up. |
| 7 | Talk to your compliance officer if your practice bills CA 125 at high volume. High-volume CA 125 billing draws more scrutiny. If this test is a significant part of your revenue cycle, a compliance review before May 15, 2026 is worth the time. This is not generic advice — it's the right call for any practice where CA 125 reimbursement is material to the bottom line. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for CA 125 Tumor Antigen Under This Policy
The policy data provided for this modification does not include specific CPT, HCPCS, or ICD-10 codes. We do not fabricate codes here — that's how billing errors happen.
What Your Team Should Reference
CA 125 tumor antigen testing is billed under standard laboratory codes. Your billing team likely already knows these codes, but confirming them against the current CMS fee schedule and your MAC's LCD is the right move before May 15, 2026.
Work with your laboratory billing staff or coding team to confirm:
- The correct CPT code for CA 125 by immunoassay currently in use at your practice
- Whether your MAC's LCD lists specific covered ICD-10 codes for this test
- The current Medicare fee schedule reimbursement rate for your region
Do not rely on codes from memory or older billing sheets. Pull the current CMS fee schedule and cross-reference against the LCD. If you're not sure which LCD applies to you, the CMS LCD database at cms.gov lets you search by MAC and contractor.
A Note on Regional Variation
CA 125 coverage under Medicare is subject to MAC-level local coverage determinations. That means the covered ICD-10 codes and documentation requirements can vary by region. What's covered in one MAC jurisdiction may face additional documentation requirements in another. Your billing guidelines need to reflect your specific MAC's LCD — not just the national policy summary.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.